Moomoo AIのまとめ
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
SeaStar Medical Holding Corporationは、医療関連のテクノロジー企業であり、2024年8月20日付でH.C. Wainwright & Co., LLCと株式市場での売り付け契約を締結しました。この契約に基づき、SeaStar Medicalは時折、Wainwrightを通じて最大2500万ドル相当の普通株式を売り出すことができます。売り出しはナスダック・キャピタル・マーケットまたは他のアメリカの既存取引市場で行われる可能性があります。Wainwrightは売り手代理人として行動し、商業上合理的な努力を行い、SeaStar Medicalの株式を売却します。売り...すべて展開
SeaStar Medical Holding Corporationは、医療関連のテクノロジー企業であり、2024年8月20日付でH.C. Wainwright & Co., LLCと株式市場での売り付け契約を締結しました。この契約に基づき、SeaStar Medicalは時折、Wainwrightを通じて最大2500万ドル相当の普通株式を売り出すことができます。売り出しはナスダック・キャピタル・マーケットまたは他のアメリカの既存取引市場で行われる可能性があります。Wainwrightは売り手代理人として行動し、商業上合理的な努力を行い、SeaStar Medicalの株式を売却します。売り付けは、SeaStar MedicalまたはWainwrightのいずれかによって契約が終了すると終了します。この措置は、SeaStar Medicalの最近の展開の後に行われました。展開内容には、小児用Selective Cytopheretic Device（SCD）向けにFDAから承認可能な通知書を受領したこと、急性腎障害を持つ成人患者におけるSCDの重要な臨床試験の開始などが含まれます。同社の普通株式とワラントはそれぞれ'ICU'と'ICUCW'のシンボルでナスダックで取引されています。
役に立った
役に立たない